

# Supplementary Material

## **1** Supplementary Data

#### 1.1 Age & referral

- 16y Recurrence, Post-Transplant Lymphoproliferative Disorder (PTLD)
- 17y Treatment control, bilateral germ cell tumors in the ovaries + multiple vascular thrombi
- *5y Treatment control, adrenocortical carcinoma with liver recurrence*
- *10y Recurrence, hepatoblastoma + residual disease in scapula*
- 13y Primary diagnosis, vertebral tumor with neuroforaminal involvement
- 15y Recurrence, anaplastic large cell lymphoma
- 15y Treatment control, mediastinal germ cell tumor + thrombosis of subclavian vein
- 10y Primary diagnosis, occult tumor in the lung
- 14y Primary diagnosis, occult malignancy
- 15y Treatment control, nasopharyngeal cancer
- 15y Treatment control, disseminated and refractory ostegenic sarcoma
- 10y Primary diagnosis, osteomyelitis in the jaw + tuberculosis
- *2y Primary diagnosis, occult cancer in the small pelvis*
- 10y Treatment control, lymphoma
- 13y Primary diagnosis, occult tumorin thoracic vertebra (Th1) seen on MR
- 16y Treatment control, melanocytic tumor
- 10y Recurrence, hepatoblastoma
- 13y Recurrence, sarcoidosis
- 10y Treatment control, Burkitt's lymphoma
- 10y Primary diagnosis, Hodgkin's lymphoma + nodular sclerosis
- 11y Treatment control, sarcoma
- 17y Recurrence /treatment control, medulloblastoma
- 8y Primary diagnosis, chronic lymphadenitis + intermittent fever
- 16y Treatment control, alveolar rhabdomyosarcoma
- 8y Primary diagnosis, abscess/endocarditis/salmonella
- 14y Treatment control, Hodgkin's lymphoma
- 7y Recurrence, infection with salmonella
- 16y Primary diagnosis, lung abscess
- 17y Primary diagnosis, residual fever
- 16y Treatment control, Hodgkin's lymphoma
- 14y Recurrence, lymphadenopathy + Griscelli syndrome + hemophagocytosis
- 16y Primary diagnosis, infection of spinal implant
- 17y Staging, lymphoma
- 15y Treatment control, lymphoma
- 15y Treatment control, osteogenic sarcoma
- 2y Treatment control, alveolar rhabdomyosarcoma
- 14y Primary diagnosis, PTLD + Epstein-Barr virus
- 2y Treatment control, disseminated alveolar rhabdomyosarcoma
- 16y Primary diagnosis, sarcoma
- 5y Treatment control, adrenocortical carcinoma with liver recurrence
- 6y Treatment control, Langerhans cell histiocytosis
- 16y Recurrence, alveolar rhabdomyosarcoma left arm
- 16y Treatment control, Hodgkin's lymphoma
- 0.25y Primary diagnosis, sarcoma
- 17y Treatment control, Hodgkin's lymphoma
- 10y Treatment control, hepatoblastoma
- 4y Primary diagnosis, osteomyelitis

- 13y Primary diagnosis, endocarditis with extra-cardial foci
- 16y Staging, multifocal infiltrations suspect of malignancy on MR
- 10y Treatment control, Hodgkin's lymphoma

## **1.2** Total list of anatomical sites

Organs

- 1 Brain
- 2 Oro/naso/hypopharynx/larynx
- 3 Thyroid gland
- 4 Lung, right
- 5 Lung, left
- 6 Pleura, right
- 7 Pleura, left
- 8 Breast, right
- 9 Breast, left
- 10 Esophagus
- 11 Liver
- 12 Pancreas
- 13 Adrenal gland, right
- 14 Adrenal gland, left
- 15 Kidney, right
- 16 Kidney, left
- 17 Spleen
- 18 Stomach
- 19 Bowel
- 20 Peritoneal
- 21 Ovary, right
- 22 Ovary, left
- 23 Uterus
- 24 Cervix
- 25 Vagina/vulva
- 26 Prostate
- 27 Penis/scrotum
- 28 Bones
- 29 Cutis/skin
- 30 Other

Lymphnodes

- 31 Head/neck, right
- 32 Head/neck, left
- 33 Axilla/subpect, right
- 34 Axilla/subpect, left
- 35 Mediastinum/hilar/retrocrural
- *36 Int mam, precardiac*
- 37 Retroperitoneal
- 38 Abdominal
- 39 Iliac, right
- 40 Iliac, left
- 41 Groin, right
- 42 Groin, left
- 43 Lnn, other

# 2 Supplementary Tables

## 2.1 Summary of statistical results from the evaluation of lesion detection.

SUPPL. TABLE 2.1 Summary of statistical results from the evaluation of lesion detection.

Acquisition grouping	Friedman's test	Corresponding pairs	Wilcoxon signed rank test
Total Findings	Significant		
Time dependent acquisitions	Significant	F150s - F300s	Significant
		F150s - F600s	Significant
		F300 - F600s	Not significant
Filter/iteration dependent acquisitions	Not significant	-	-
Organ Findings	Not significant		
Time dependent acquisitions	NA	-	-
Filter/iteration dependent acquisitions	NA	-	-
Lymph node Findings	Significant		
Time dependent acquisitions	Significant	F150s - F300s	Significant
		F150s - F600s	Significant
		F150s – NF4i300s	NS
		F150s – NF6i300s	NS
		F300s - F600s	Not significant
	Significant	F300s – NF4i300s	Not significant
Filter/iteration dependent acquisitions		F300s – NF6i300s	Not significant
		F600s - NF4i300s	NS
		F600s – NF6i300s	NS
		NF4i300s – NF6i300s	Not significant

Suppl. table 2.1: NA: Not applicable. NS: Not supplied. These pairs were included as possible pairs in the Bonferroni correction, but have no relevant outcome and are therefore not included.

# 2.2 Significance of Friedman's test

#### SUPPL. TABLE 2.2 Significance of Friedman's test

P-value of	All five reconstructions	<b>Time dependent</b> F150s, F300s, F600s	<b>Filter/iteration dependent</b> F300s, NF4i300s, NF6i300s
Total image findings	<0.001*	<0.001*	0.058
Organ findings	0.837	NA	NA
Lymph node findings	<0.001*	<0.001*	0.045*

Suppl. table 2.2: All P-values of the performed Friedman's test. Significance marked with \*. Friedman's test was performed for the time and filter/iteration dependent acquisitions when the initial for all five reconstructions was significant. Pairwise comparison was indicated when significant values were found in the time and filter/iteration dependent groupings. NA: Not applicable

## 2.3 Time dependent Wilcoxon rank test significance.

	Compared time dependent acquisitions		
	$F150s \rightarrow F300s$	$F300s \rightarrow F600s$	$F150s \rightarrow F600s$
Total lesions			
Increase in lesions	+150*	+9	+159*
Р	<0.001	0.039	<0.001
P <sub>B</sub>	0.007	0.512	0.006
Organ lesions			
Increase in lesions	+6	0	+6
Р	NA	NA	NA
PB	-	-	-
Lymph node lesions			
Increase in lesions	+144*	+9	+153*
Р	0.001	0.039	0.001
P <sub>B</sub>	0.019	0.512	0.019

Suppl. Table 2.3: All P-values for the paired comparison of lesion detection between the time dependent acquisitions. Bonferroni correction by a factor of 13 P-value ( $P_B$ ). NA: Not applicable

# 2.4 Filter/iteration dependent Wilcoxon rank test significance

#### SUPPL. TABLE 2.4 Filter/iteration dependent Wilcoxon rank test significance

	Compared filter/iteration dependent acquisitions			
	$F300s \rightarrow NF4i300s$	$NF4i300s \rightarrow NF6i300s$	$F300s \rightarrow NF6i300s$	
Total lesions				
Increase in lesions	+20	+14	+34	
Р	NA	NA	NA	
PB	-	-	-	
Organ lesions				
Increase in lesions	-1	0	-1	
Р	NA	NA	NA	
PB	-	-	-	
Lymph node lesions				
Increase in lesions	+21	+14	+35	
Р	0.181	0.017	0.062	
P <sub>B</sub>	-	0.218	-	

Suppl. Table 2.4: All P-values for the paired comparison of lesion detection between the filter and iteration dependent acquisitions. Bonferroni correction by a factor of 13 ( $P_B$ ). NA: Not applicable